Literature DB >> 7488368

Task force on recurrent respiratory papillomas. A preliminary report.

C S Derkay1.   

Abstract

OBJECTIVE: To obtain pilot data about the incidence, need for surgical intervention, and demographics of recurrent respiratory papillomas in the United States.
DESIGN: Otolaryngologists were surveyed using a questionnaire with structured and open-ended questions. PARTICIPANTS: One thousand board-certified otolaryngologists practicing in the United States as of January 1, 1993, through a random mailing list provided by the American Academy of Otolaryngology-Head and Neck Surgery and all active US members of the American Society of Pediatric Otolaryngology and the American Bronchoesophagological Association. A total of 1346 questionnaires were distributed. MAIN OUTCOME MEASURES: Physician's responses to questions about their current patient load of children and adults with recurrent respiratory papillomas, their surgical and anesthetic management of the disease, and their clinical experiences with risk factors for developing recurrent respiratory papillomas.
RESULTS: Projected totals for recurrent respiratory papillomas among children were 2354 new cases (95% confidence interval [CI], 1448 to 3260) and 5970 active cases (95% CI, 3465 to 8474), requiring 16,597 surgical procedures (95% CI, 6938 to 26,255) at a cost of $109 million (95% CI, $45 to 172 million) for March 1, 1993 to March 31, 1994. Projected totals for adult recurrent respiratory papillomas were 3623 new cases (95% CI, 2359 to 4887) and 9015 active cases (95% CI, 6435 to 11,591) requiring 9284 surgical procedures (95% CI, 6003 to 12,565) at a cost of $42 million (95% CI, $27 to $59 million) for March 1, 1993 to March 31, 1994. The incidence of recurrent respiratory papillomas among children is estimated at 4.3 per 100,000; among adults, 1.8 per 100,000. The carbon dioxide laser was favored by 92% of respondents. No consensus was reached on the role for cesarean section. Forty-six percent of respondents favored the use of a laser-safe endotracheal tube for anesthetic management.
CONCLUSION: A registry of patients with recurrent respiratory papillomas would benefit future research protocols and provide long-term follow-up of patients.

Entities:  

Mesh:

Year:  1995        PMID: 7488368     DOI: 10.1001/archotol.1995.01890120044008

Source DB:  PubMed          Journal:  Arch Otolaryngol Head Neck Surg        ISSN: 0886-4470


  68 in total

1.  Clinical efficiency of quadrivalent HPV (types 6/11/16/18) vaccine in patients with recurrent respiratory papillomatosis.

Authors:  Magdalena Chirilă; Sorana D Bolboacă
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-05       Impact factor: 2.503

2.  Infectivity of murine papillomavirus in the surgical byproducts of treated tail warts.

Authors:  Simon R Best; Daniel Esquivel; Rebecca Mellinger-Pilgrim; Richard B S Roden; Michael J Pitman
Journal:  Laryngoscope       Date:  2019-05-01       Impact factor: 3.325

3.  Office-based Management of Recurrent Respiratory Papilloma.

Authors:  Kevin M Motz; Alexander T Hillel
Journal:  Curr Otorhinolaryngol Rep       Date:  2016-03-31

4.  Recurrent respiratory pappillomatosis: national registry.

Authors:  Anupam Mishra; D B Singh; Veerendra Verma
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2012-03-29

5.  Utility of Optical Coherence Tomography for Guiding Laser Therapy Among Patients With Recurrent Respiratory Papillomatosis.

Authors:  Fouzi Benboujja; Sarah Bowe; Caroline Boudoux; Christopher Hartnick
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2018-09-01       Impact factor: 6.223

6.  Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial.

Authors:  Cornelia L Trimble; Matthew P Morrow; Kimberly A Kraynyak; Xuefei Shen; Michael Dallas; Jian Yan; Lance Edwards; R Lamar Parker; Lynette Denny; Mary Giffear; Ami Shah Brown; Kathleen Marcozzi-Pierce; Divya Shah; Anna M Slager; Albert J Sylvester; Amir Khan; Kate E Broderick; Robert J Juba; Timothy A Herring; Jean Boyer; Jessica Lee; Niranjan Y Sardesai; David B Weiner; Mark L Bagarazzi
Journal:  Lancet       Date:  2015-09-17       Impact factor: 79.321

Review 7.  The economic burden of noncervical human papillomavirus disease in the United States.

Authors:  Delphine Hu; Sue Goldie
Journal:  Am J Obstet Gynecol       Date:  2008-05       Impact factor: 8.661

8.  Human papilloma virus vaccination in patients with an aggressive course of recurrent respiratory papillomatosis.

Authors:  Irena Hočevar-Boltežar; Mojca Matičič; Maja Sereg-Bahar; Nina Gale; Mario Poljak; Boštjan Kocjan; Miha Zargi
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-06-26       Impact factor: 2.503

9.  E6 proteins from low-risk human papillomavirus types 6 and 11 are able to protect keratinocytes from apoptosis via Bak degradation.

Authors:  Michael P Underbrink; Crystal Dupuis; Jia Wang; Stephen K Tyring
Journal:  J Gen Virol       Date:  2016-01-07       Impact factor: 3.891

10.  Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States.

Authors:  Jane J Kim; Sue J Goldie
Journal:  BMJ       Date:  2009-10-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.